Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans

被引:97
作者
Cipolla, David [1 ]
Shekunov, Boris [2 ]
Blanchard, Jim [1 ]
Hickey, Anthony [3 ]
机构
[1] Aradigm Corp, Hayward, CA 94545 USA
[2] Shire Corp, Wayne, PA 19087 USA
[3] RTI Int, Res Triangle Pk, NC 27709 USA
关键词
Pulmonary delivery; Liposomes; Solid lipid nanoparticles; Nanostructured lipid carriers; Lipid microparticles; LIPOSOMAL AMPHOTERICIN-B; AIR INHALED INSULIN; LARGE-POROUS-PARTICLES; SUPERCRITICAL-FLUID EXTRACTION; CYSTIC FIBROSIS BRONCHIECTASIS; VASOACTIVE-INTESTINAL-PEPTIDE; DOSE DELIVERY CHARACTERISTICS; TOBRAMYCIN INHALATION POWDER; REGIONAL LUNG DEPOSITION; RAT ALVEOLAR MACROPHAGES;
D O I
10.1016/j.addr.2014.05.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A number of lipid-based technologies have been applied to pharmaceuticals to modify their drug release characteristics, and additionally, to improve the drug loading for poorly soluble drugs. These technologies, including solid-state lipid microparticles, many of which are porous in nature, liposomes, solid lipid nanoparticles and nanostructured lipid carriers, are increasingly being developed for inhalation applications. This article provides a review of the rationale for the use of these technologies in the pulmonary delivery of drugs, and summarizes the manufacturing processes and their limitations, the in vitro and in vivo performance of these systems, the safety of these lipid-based systems in the lung, and their promise for commercialization. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:53 / 80
页数:28
相关论文
共 336 条